Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337829 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
A Phase 2 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02337829 is a Phase 2 study that has completed, run by Acerta Pharma. The registered enrollment target is 48 participants.
The verdict
NCT02337829, a Phase 2 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Interventions
- DRUG Acalabrutinib (Arm A)
- DRUG Acalabrutinib (Arm B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-01-12 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337829
The ClinicalTrials.gov registry entry for NCT02337829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Acalabrutinib (Arm A) is the first listed.
NCT02337829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02337829 about?
NCT02337829 is a clinical study titled "Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL". This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
What is the current status of trial NCT02337829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-01-12. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT02337829?
The interventions under investigation include: Acalabrutinib (Arm A) (DRUG), Acalabrutinib (Arm B) (DRUG).
Who is sponsoring clinical trial NCT02337829?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.